Mohan Bala
Corporate Officer/Principal presso MERSANA THERAPEUTICS, INC.
Patrimonio netto: 62 953 $ in data 31/03/2024
Profilo
Mohan Bala's career history includes current and former positions as well as education.
Currently, Dr. Bala is the Chief Development Officer & Senior Vice President at Mersana Therapeutics, Inc. Prior to this, Dr. Bala held the position of Chief Operating Officer at Constellation Pharmaceuticals, Inc. and Vice President of Lead Development Program at Tesaro, Inc. Dr. Bala's education includes an MBA and a doctorate from The University of Chicago.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 16/01/2024 | 14 052 ( 0.01% ) | 62 953 $ | 31/03/2024 |
Posizioni attive di Mohan Bala
| Società | Posizione | Inizio |
|---|---|---|
| MERSANA THERAPEUTICS, INC. | Corporate Officer/Principal | 25/10/2021 |
Precedenti posizioni note di Mohan Bala
| Società | Posizione | Fine |
|---|---|---|
| TESARO INC | Corporate Officer/Principal | - |
| CONSTELLATION PHARMACEUTICALS, INC. | Chief Operating Officer | - |
Formazione di Mohan Bala
| The University of Chicago | Doctorate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| MERSANA THERAPEUTICS, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Tesaro, Inc.
 Tesaro, Inc. Pharmaceuticals: MajorHealth Technology TESARO, Inc. is an oncology-focused biopharmaceutical company, which engages in the research and development of biopharmaceutical products. The firm offers Niraparib products. The company was founded by Leon Oliver Moulder, Jr., Mary Lynne Hedley, and Richard J. Rodgers on March 26, 2010 and is headquartered in Waltham, MA. | Health Technology |
Constellation Pharmaceuticals, Inc.
 Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The firm utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Mohan Bala
